Holen Sie sich die Stockscreener-App
4.42
2.08%
0.09
Handel nachbörslich:
4.45
0.03
+0.68%
Schlusskurs vom Vortag:
$4.33
Offen:
$4.35
24-Stunden-Volumen:
1.19M
Relative Volume:
0.97
Marktkapitalisierung:
$252.16M
Einnahmen:
$5.82M
Nettoeinkommen (Verlust:
$71.18M
KGV:
4.4324
EPS:
0.9972
Netto-Cashflow:
$-84.30M
1W Leistung:
-2.86%
1M Leistung:
-16.60%
6M Leistung:
-17.54%
1J Leistung:
-11.60%
1-Tages-Spanne:
$4.35
$4.52
1-Wochen-Bereich:
$4.285
$4.625
52-Wochen-Spanne:
$3.9328
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Firmenname
Abeona Therapeutics Inc
Sektor
Branche
Telefon
646-813-4701
Adresse
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
4.42 | 247.02M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-03-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-30 | Eingeleitet | Stifel | Buy |
| 2020-11-11 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-02-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-10 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2019-08-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-06-27 | Eingeleitet | Mizuho | Buy |
| 2018-10-12 | Eingeleitet | Mizuho | Buy |
| 2018-06-05 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-11-08 | Eingeleitet | SunTrust | Buy |
| 2017-10-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Eingeleitet | Citigroup | Buy |
| 2017-10-05 | Bestätigt | Maxim Group | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-18 | Bestätigt | Maxim Group | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-01-06 | Eingeleitet | Jefferies | Buy |
| 2016-09-29 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Abeona Therapeutics Inc Aktie (ABEO) Neueste Nachrichten
Meme Stocks: Does Abeona Therapeutics Inc have strong EBITDA margins2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2025 earnings call transcript - MSN
HC Wainwright Issues Pessimistic Outlook for ABEO Earnings - MarketBeat
Abeona Therapeutics Adopts Third Amended and Restated Bylaws Effective March 16, 2026 - Minichart
Form 8K Abeona Therapeutics Inc For: 20 March By Investing.com - Investing.com Australia
Form 8K Abeona Therapeutics Inc For: 20 March - Investing.com
Abeona Therapeutics Tightens Shareholder Meeting and Governance Rules - TipRanks
Abeona (NASDAQ: ABEO) tightens bylaws on meetings and director nominations - Stock Titan
Abeona Therapeutics Earnings Notes - Trefis
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB - Seeking Alpha
HC Wainwright & Co. Reiterates Buy Rating for Abeona Therapeutics (ABEO) | ABEO Stock News - GuruFocus
Abeona Therapeutics (NASDAQ:ABEO) Earns Buy Rating from HC Wainwright - MarketBeat
Abeona Therapeutics (ABEO) Receives a Buy from Oppenheimer - The Globe and Mail
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2025 Earnings Call Transcript - Insider Monkey
Abeona Therapeutics Balances Big Windfall With Slow Ramp - The Globe and Mail
Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point (NASDAQ:ABEO) - Seeking Alpha
Abeona Therapeutics (ABEO) One Off US$152.4m Gain Tests Bullish Profitability Narrative - simplywall.st
Abeona targets activation of 7 QTCs for ZEVASKYN by end of 2026 as patient demand doubles - MSN
Stifel cuts Abeona Therapeutics stock price target on sales timing By Investing.com - Investing.com Australia
Oppenheimer reiterates Abeona Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Stifel cuts Abeona Therapeutics stock price target on sales timing - Investing.com
Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: - GuruFocus
Abeona Therapeutics Reports 2025 Financial Results, ZEVASKYN Launch Momentum, and $191.4M Cash Position - Minichart
Abeona (ABEO) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
ABEO: Strong launch momentum, profitability, and expanding access position ZEVASKYN for growth - TradingView
Abeona (ABEO) Q4 2025 Earnings Call Transcript - The Globe and Mail
Abeona Therapeutics Q4 Earnings Call Highlights - MarketBeat
ABEO: 2025 marked a profitable year with ZEVASKYN's launch, expanding access, and robust financials - TradingView
Earnings call transcript: Abeona Therapeutics Q4 2025 shows revenue growth - Investing.com
Abeona Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Abeona Therapeutics 2025 Financial Results: Annual Profit and Q4 BeatNews and Statistics - IndexBox
Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Abeona Therapeutics (ABEO) Reports Mixed FY Results with Revenue Beat - GuruFocus
Abeona Therapeutics FY income from operations USD -89.448 million versus Ibes estimate USD -78.4 million - marketscreener.com
Abeona Therapeutics (NASDAQ:ABEO) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
ABEO Exceeds Revenue Expectations with Strong Biopsy and Treatme - GuruFocus
ABEONA THERAPEUTICS ($ABEO) Releases Q4 2025 Earnings - Quiver Quantitative
The latest financial data released by biotechnology company Abeona Therapeutics Inc shows its annual operating income recorded at -89.448 millions USD. - Bitget
Abeona Therapeutics: Fourth Quarter Earnings Overview - Bitget
Abeona Therapeutics 10-K: $5.82M Revenue, $71.18M Net Income - TradingView
Abeona Therapeutics: Q4 Earnings Snapshot - Barchart.com
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates - The Manila Times
Abeona (NASDAQ: ABEO) shifts to commercial stage with ZEVASKYN and $155M PRV cash - Stock Titan
Abeona Therapeutics (Nasdaq: ABEO) turns 2025 profit on PRV sale and builds cash - Stock Titan
First ZEVASKYN patients treated as Abeona banks $191M cash - Stock Titan
Earnings Scheduled For March 17, 2026 - Benzinga
Abeona Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Abeona Therapeutics CFO Vazzano sells $3.7k in stock By Investing.com - Investing.com Australia
Abeona Therapeutics CFO Vazzano sells $3.7k in stock - Investing.com
ABEO SEC FilingsAbeona Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Abeona Therapeutics FY 2025 earnings preview - MSN
Finanzdaten der Abeona Therapeutics Inc-Aktie (ABEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Abeona Therapeutics Inc-Aktie (ABEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Vazzano Joseph Walter | Chief Financial Officer |
Mar 16 '26 |
Sale |
4.76 |
785 |
3,737 |
567,775 |
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):